The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
Open accessPublished version of a preprint
Abstract
Background: Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy. We sought to determine to what extent this immune evasion is due to intrinsic properties of the tumor cells versus the specialized immune context of the brain, and if it can be reversed. Methods: We used CyTOF mass cytometry to compare the tumor immune microenvironments (TIME) of human tumors that are generally ICI-refractory (GBM and sarcoma) or ICI-responsive (renal cell carcinoma), as well as mouse models of GBM that are ICI-responsive (GL261) or ICI-refractory (SB28). We further compared SB28 tumors grown intracerebrally versus subcutaneously to determine how tumor site affects TIME and responsiveness to dual CTLA-4/PD-1 blockade. Informed by these data, we explored rational immunotherapeutic combinations. Results: ICI-sensitivity in human and mouse tumors was associated with increased T cells and dendritic cells (DCs), and fewer myeloid cells, in particular PD-L1+ tumor-associated macrophages. The SB28 mouse model of GBM responded to ICI when grown subcutaneously but not intracerebrally, providing a system to explore mechanisms underlying ICI resistance in GBM. The response to ICI in the subcutaneous SB28 model required CD4 T cells and NK cells, but not CD8 T cells. Recombinant FLT3L expanded DCs, improved antigen-specific T cell priming, and prolonged survival of mice with intracerebral SB28 tumors, but at the cost of increased Tregs. Targeting PD-L1 also prolonged survival, especially when combined with stereotactic radiation. Conclusions: Our data suggest that a major obstacle for effective immunotherapy of GBM is poor antigen presentation in the brain, rather than intrinsic immunosuppressive properties of GBM tumor cells. Deep immune profiling identified DCs and PD-L1+ tumor-associated macrophages as promising targetable cell populations, which was confirmed using therapeutic interventions in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Deep immune profiling of immune checkpoint inhibitor (ICI)‐refractory and responsive in mouse models using Cytometry by the time of flight (CyTOF) showed that ICI‐refractory in glioma tumors was associated with accumulating PD‐L1+ TAMs and lack of MHC‐II+ antigen‐presenting cells [289].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [289]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
(2008) · Journal of Machine Learning Research · Cited by 33,051
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
Self-citation
Cited by
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
Khan, F., Pang, L., Dunterman, M., Lesniak, M. S., Heimberger, A. B., & Chen, P. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163446 · Cited by 414
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer
Dong, S., Liu, X., Bi, Y., Wang, Y., Antony, A., Lee, D., Huntoon, K. M., Jeong, S. D., Ma, Y., Li, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42365-5 · Cited by 136
TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma
Sun, R., Han, R., McCornack, C., Khan, S., Tabor, G. T., Chen, Y., Hou, J., Jiang, H., Schoch, K. M., Mao, D. D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3559 · Cited by 119
Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
An, H. J., Chon, H. J., & Kim, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179414 · Cited by 111
Metadata
- Authors
- Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., McHenry, L. K., Nasholm, N. M., Chuntova, P., Sundström, A., Genoud, V., Shahani, S. A., Wang, L. D., Brown, C. E., Walker, P. R., Swartling, F. J., Fong, L., Okada, H., Weiss, W. A., & Hellström, M.
- Affiliations
- University of California, San Francisco (US)
- Uppsala University (SE)
- University of Geneva (CH)
- City Of Hope National Medical Center (US)
- Corresponding author
- Okada, Hideho
- Weiss, William A
- Hellström, Mats
- ORCID
- Simonds, Erin F
- Lu, Edbert D
- Badillo, Oscar
- Karimi, Shokoufeh
- Tamaki, Whitney
- Rancan, Chiara
- Downey, Kira M
- Sinha, Meenal
- McHenry, Lauren K
- Nasholm, Nicole M
- Chuntova, Pavlina
- Sundström, Anders
- Genoud, Vassilis
- Wang, Leo D
- Brown, Christine E
- Walker, Paul R
- Swartling, Fredrik J
- Fong, Lawrence
- Okada, Hideho
- Weiss, William A
- Hellström, Mats
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-06
- Volume
- 9
- Issue
- 6
- Pages
- e002181
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8183210
- OpenAlex
- W3165096196
- Cited by
- 119
- References
- 59
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 25 · 2023: 23 · 2022: 15 · 2021: 2
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (P30CA82103, P30DK063720, P50CA097257, R01CA221969, R33CA183692, S101S10OD018040-01, U01CA176287, R35NS105068, R01CA222965, K08CA201591)
- Cancer Research UK (A28592)
- Samuel Waxman Cancer Research Foundation
- Alex's Lemonade Stand Foundation for Childhood Cancer (YIA)
- Swedish Cancer Society
- Damon Runyon Cancer Research Foundation (DRG-2190-14)
- MH: Wenner-Gren Foundations
- Parker Institute for Cancer Immunotherapy
- Swedish Research Council (2018-05973)
- California Institute for Regenerative Medicine (CLIN2-10248)
- Prostate Cancer Foundation (Challenge Award)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- glioblastoma, immune checkpoint inhibitors, immune evasion, tumor immune microenvironment, PD-L1, tumor-associated macrophages, dendritic cells, antigen presentation, Flt3L, regulatory T cells, CD4+ T cells, natural killer cells, immunotherapy resistance
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Brain Neoplasms, Glioblastoma, Humans, Membrane Proteins, Tumor Escape, Xenograft Model Antitumor Assays, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. https://app.cochat.ai/papers/10.1136/jitc-2020-002181
- The paper
- Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., McHenry, L. K., Nasholm, N. M., Chuntova, P., Sundström, A., Genoud, V., Shahani, S. A., Wang, L. D., Brown, C. E., Walker, P. R., . . . Hellström, M. (2021). Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-002181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.